Biopharma and med-tech companies raising money in public or private financings, including: Achieve Life Sciences, Acurx, Adlai, Meiragtx, Onward, Pamdx.
Kailera Therapeutics Inc.’s “obesity-first” approach continues to resonate with investors, with the company pricing an upsized IPO, offering 39 million shares at $16 apiece for gross proceeds of $625 million. Full exercise of the underwriters’ option could add another $93.8 million, bringing the total to nearly $719 million, easily topping Sana Biotechnology Inc.’s $675.6 million 2021 IPO and setting a new record for U.S. biopharma IPOs, according to BioWorld data.
Biopharma and med-tech companies raising money in public or private financings, including: Allogene, Beeline, Heartbeam, Sonire, Telix, Terremoto, Traws, Verismo.
Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent years. The 2026 total exceeds $6.45 billion in Q1 2024 and $4.69 billion in Q1 2023, indicating continued recovery from the weaker funding environment that followed the 2021 peak. While still below the $16.59 billion recorded in Q1 2019 and the pandemic-era highs, the data suggest that financing activity has stabilized at a higher baseline, with 2026 maintaining momentum despite a slight year-over-year pullback.
RNA epigenetics specialist Storm Therapeutics Ltd. has closed a $56 million series C to fund phase II development of its lead RNA enzyme inhibitor, STC-15, in treating myo- and liposarcomas, and announced that the first patient has been treated in the trial.
In what shakes out to be the largest follow-on stock offering in biopharma history, Revolution Medicines Inc., an oncology company that was the subject of buyout rumors earlier this year, priced 10.56 million shares to raise $1.5 billion just two days after wowing investors with top-line phase III data of its RAS inhibitor daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma.
Oricell Therapeutics Holdings Ltd closed a $110 million pre-IPO round to expand its global footprint and advance its lead candidate, a GPC3-targeted autologous CAR T therapy for liver cancer to registrational trials.
Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development.
RSS
